| Identification | Back Directory | [Name]
Fenofibrate-d6 | [CAS]
1092484-56-4 | [Synonyms]
Lipsin-d6
Nolipax-d6
Liposit-d6
LF 178-d6
Lipirex-d6
Lipoclar-d6
Lipofene-d6
Lipantil-d6
MeltDose-d6
Lipanthyl-d6
NSC 281319-d6
Fenofibrate-d6
Lipidil Supra-d6
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methyl-propanoic Acid-d6 1-Methylethyl Ester | [Molecular Formula]
C20H21ClO4 | [MOL File]
1092484-56-4.mol | [Molecular Weight]
360.831 |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
70-720C | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), Methanol (Sightly) | [form ]
Solid | [color ]
White to Off-White | [CAS DataBase Reference]
1092484-56-4 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Antilipemic. It is a lipid regulating drug. Increases high density lipoprotein levels by reducing cholesteryl ester transfer protein expresion. | [Description]
Fenofibrate-d6 is intended for use as an internal standard for the quantification of fenofibrate by GC- or LC-MS. Fenofibrate is an agonist of peroxisome proliferator-activated receptor α (PPARα) with EC50 values of 18 and 30 μM for mouse and human receptors, respectively, in a transactivation assay. It is selective for PPARα over PPARγ (EC50s = 300 and 200 μM for mouse and human receptors, respectively) and lacks activity at mouse and human PPARδ at a concentration of 100 μM. In vivo, fenofibrate (50-100 mg/kg) reduces plasma levels of triglycerides, C-reactive protein, and malondialdehyde (MDA) in mice with fructose-induced hypertriglycemia in a dose-dependent manner. It decreases glomerular and tubular atrophy and necrosis induced by cisplatin in rat kidney when administered at a dose of 100 mg/kg. Fenofibrate also reduces the number of pulmonary lesions induced by 4-nitroquinoline 1-oxide (4-NQO) in lung of Tsumura Suzuki obese diabetic (TSOD) mice. | [IC 50]
CYP2; CYP3 | [storage]
Store at -20°C | [References]
[1] TIMOTHY M. WILLSON. The PPARs: From Orphan Receptors to Drug Discovery?[J]. Journal of Medicinal Chemistry, 2000, 43 4: 527-550. DOI: 10.1021/jm990554g
[2] BING SUN. Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia.[J]. Lipids in Health and Disease, 2015, 14: 27. DOI: 10.1186/s12944-015-0032-3
[3] M. HELMY M E M M Helmy. Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs[J]. PLoS ONE, 2015, 10 1. DOI: 10.1371/journal.pone.0142303
[4] TOSHIYA KUNO. The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice.[J]. International Journal of Molecular Sciences, 2014, 15 5: 9160-9172. DOI: 10.3390/ijms15059160 |
|
| Company Name: |
SYNTHENTA PVT LTD
|
| Tel: |
+91-7416102217 +91-7416102217 |
| Website: |
www.synthenta.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|